Interferon alpha (Dainippon Sumitomo Pharma)

干扰素 α-n1

Report date: 2025/03/05 15:36:25

Base Information

Drug NameInterferon alpha (Dainippon Sumitomo Pharma)
Drug Alias NameInterferon-alfa (Dainippon Sumitomo Pharma)Interferon-α NAMALWAInterferon alpha-n1 (Dainippon Sumitomo Pharma)IFN-α (Dainippon Sumitomo Pharma)Sumiferon
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsFibrosisMultiple MyelomaCarcinoma, Renal Cell +[6] 
Global Approved IndicationsFibrosisMultiple MyelomaCarcinoma, Renal Cell +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date1997/09/17
Country/TerritoryJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesDainippon Sumitomo Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Dainippon
Inactive CompaniesN/A
Active IndicationsFibrosisMultiple MyelomaCarcinoma, Renal Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB06
Related LinksDrugBankKEGG